19 reports

  • STATINS
  • STATINS

About Hypercholesterolemia Hypercholesterolemia is characterized by high levels of total cholesterol and LDL-C in the blood. High cholesterol levels can cause CVDs such as stroke and atherosclerosis. The typical range of total blood cholesterol is 140-200 mg/dL.Blood cholesterol contains individual components such as LDL-C and HDL-C....

  • Statins
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • STATINS
  • INCREASING USE OF STATINS

About Dyslipidemia Drugs Lipid refers to fat comprising proteins and carbohydrates. Cholesterol and triglycerides are lipids that are stored in the human body and serve as a source of energy. Dyslipidaemia is the imbalance in the lipid level in the bloodstream. It is characterized by high levels of total cholesterol and low-density...

  • Cardiovascular Disease
  • Cholesterol
  • Lipid Modifying Drug
  • Statins
  • AstraZeneca PLC
  • 10.1 TYPE 1 STATINS
  • 10.2 TYPE 2 STATINS

About Statin Statin is a structural analog of HMG-CoA enzyme and is effective in reducing LDL. It shows its pharmaceutical action by inhibiting the key enzyme involved in cholesterol synthesis, which is called HMG-CoA reductase. Therefore, statin is referred to HMG-CoA reductase inhibitors. Statin has been associated with a beneficial effect...

  • Statins
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • CRESTOR (ROSUVASTATIN) SWOT ANALYSIS, 2014
  • ZOCOR (SIMVASTATIN) SWOT ANALYSIS, 2014

Dyslipidemia - 5EU Drug Forecast and Market Analysis to 2023 Summary GlobalData estimates that the total market size for the 8MM in 2013 was $15.4bn, comprised of $11.0bn in branded drug sales (72%) and $4.4bn in generic sales (28%). GlobalData expects that the dyslipidemia drug market will grow at a CAGR of 9.4% over...

  • Statins
  • World
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.
  • CRESTOR (ROSUVASTATIN) SWOT ANALYSIS, 2014
  • ZOCOR (SIMVASTATIN) SWOT ANALYSIS, 2014

Dyslipidemia - US Drug Forecast and Market Analysis to 2023 Summary GlobalData estimates that the total market size for the 8MM in 2013 was $15.4bn, comprised of $11.0bn in branded drug sales (72%) and $4.4bn in generic sales (28%). GlobalData expects that the dyslipidemia drug market will grow at a CAGR of 9.4% over the...

  • Statins
  • World
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.
  • CRESTOR (ROSUVASTATIN) SWOT ANALYSIS, 2014
  • ZOCOR (SIMVASTATIN) SWOT ANALYSIS, 2014

Dyslipidemia - China Drug Forecast and Market Analysis to 2023 Summary GlobalData estimates that the total market size for the 8MM in 2013 was $15.4bn, comprised of $11.0bn in branded drug sales (72%) and $4.4bn in generic sales (28%). GlobalData expects that the dyslipidemia drug market will grow at a CAGR of 9.4% over...

  • Statins
  • World
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.
  • CRESTOR (ROSUVASTATIN) SWOT ANALYSIS, 2014
  • ZOCOR (SIMVASTATIN) SWOT ANALYSIS, 2014

Dyslipidemia - Japan Drug Forecast and Market Analysis to 2023 Summary GlobalData estimates that the total market size for the 8MM in 2013 was $15.4bn, comprised of $11.0bn in branded drug sales (72%) and $4.4bn in generic sales (28%). GlobalData expects that the dyslipidemia drug market will grow at a CAGR of 9.4% over...

  • Statins
  • World
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.

Part ##.

  • Clinical Trial
  • Drug Discovery And Development
  • Statins
  • World
  • Merck & Co., Inc.
  • Mar 27, 2007: Merck And Schering To Develop Zetia/Lipitor Combo As Focus On Reducing Bad Cholesterol Returns
  • May 03, 2013: Merck Gets FDA Approval For Liptruzeta For Treatment Of Primary Or Mixed Hyperlipidemia

Niemann Pick C1 Like Protein 1 (NPC1L1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Niemann Pick C1 Like Protein 1 (NPC1L1) - Pipeline Review, H2 2016’, provides in depth analysis on Niemann Pick C1 Like Protein 1 (NPC1L1) targeted pipeline therapeutics. The report provides comprehensive information...

  • Lipid Modifying Drug
  • Statins
  • United States
  • Product Initiative
  • Merck & Co., Inc.
  • Mar 27, 2007: Merck And Schering To Develop Zetia/Lipitor Combo As Focus On Reducing Bad Cholesterol Returns
  • May 03, 2013: Merck Gets FDA Approval For Liptruzeta For Treatment Of Primary Or Mixed Hyperlipidemia

Niemann Pick C1 Like Protein 1 (NPC1L1) - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Niemann Pick C1 Like Protein 1 (NPC1L1) - Pipeline Review, H1 2016’, provides in depth analysis on Niemann Pick C1 Like Protein 1 (NPC1L1) targeted pipeline therapeutics. The report provides comprehensive information...

  • Statins
  • South Korea
  • United States
  • World
  • Product Initiative
  • BEMPEDOIC ACID - DRUG PROFILE
  • Research and Development Brief

For the ## patients reported here, all were receiving maximum doses of statin plus ezetimibe with one patient additionally receiving lomitapide ## mg.

  • Cholesterol
  • Chronic Disease
  • Pharmaceutical
  • Statins
  • Amarin Corporation plc
  • Target
  • Target

Lipid Disorders Global Clinical Trials Review, H2, 2017 Summary GlobalData’s clinical trial report, “Lipid Disorders Global Clinical Trials Review, H2, 2017" provides an overview of Lipid Disorders clinical trials scenario. This report provides top line data relating to the clinical trials on Lipid...

  • Clinical Trial
  • Lipid Modifying Drug
  • Pharmaceutical
  • Statins
  • World
  • Target
  • Clinical Trial profile. 28 Trial Title

Dyslipidemia Global Clinical Trials Review, H2, 2017 Summary GlobalData’s clinical trial report, “Dyslipidemia Global Clinical Trials Review, H2, 2017" provides an overview of Dyslipidemia clinical trials scenario. This report provides top line data relating to the clinical trials on Dyslipidemia. Report includes an...

  • Cholesterol
  • Clinical Trial
  • Lipid Modifying Drug
  • Statins
  • World
  • Target
  • Official Title

Arteriosclerosis Global Clinical Trials Review, H1, 2017 Summary GlobalData’s clinical trial report, “Arteriosclerosis Global Clinical Trials Review, H1, 2017" provides an overview of Arteriosclerosis clinical trials scenario. This report provides top line data relating to the clinical trials on Arteriosclerosis. Report...

  • Cardiovascular Disease
  • Clinical Trial
  • Lipid Modifying Drug
  • Statins
  • World
  • Mar 18, 2017: No Benefit of Synthetic HDL-C on Arterial Plaque
  • ATHEROSCLEROSIS THERAPEUTICS CLINICAL TRIALS, GLOBAL, ONGOING CLINICAL TRIALS BY PROMINENT DRUGS, 2017*

In the E. U., Praluent is approved for the treatment of adult patients with primary hypercholesterolemia (HeFH and non-familial) or mixed dyslipidemia as an adjunct to diet: a) in combination with a statin, or statin with other lipid-lowering therapies in patients unable to reach th

  • Cardiovascular Disease
  • Clinical Trial
  • Lipid Modifying Drug
  • Statins
  • World

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Cardiovascular Disease
  • Clinical Trial
  • Statins
  • World
  • Product Initiative
  • Clinical Trial profile. 17 Trial Title
  • Clinical Trial profile. 25 Trial Title

Arteriosclerosis Global Clinical Trials Review, H2, 2016 Summary GlobalData's clinical trial report, “Arteriosclerosis Global Clinical Trials Review, H2, 2016" provides an overview of Arteriosclerosis clinical trials scenario. This report provides top line data relating to the clinical trials on Arteriosclerosis. Report...

  • Cardiovascular Disease
  • Lipid Modifying Drug
  • Pharmaceutical
  • Statins
  • World
  • GLOBAL MARKETS DIRECT REPORT COVERAGE
  • most common adverse events (AEs) in this trial were nasopharyngitis, injection-site reaction and headache.

Hyperlipidemia - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Hyperlipidemia - Pipeline Review, H1 2016’, provides an overview of the Hyperlipidemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hyperlipidemia, complete with analysis by...

  • Endocrine Disease
  • Statins
  • United States
  • Company
  • Product Initiative
  • atorvastatin calcium Product Description
  • simvastatin Product Description

Oxford Pharmascience Group Plc - Product Pipeline Review - 2015 Summary Global Markets Direct’s, ‘Oxford Pharmascience Group Plc - Product Pipeline Review - 2015’, provides an overview of the Oxford Pharmascience Group Plc’s pharmaceutical research and development focus. This report provides comprehensive information...

  • Research And Development
  • Statins
  • Therapy
  • World
  • Company Operations